Answering important questions about human disease mechanism, diagnosis and therapy requires that molecular tools be coupled effectively to detailed clinical phenotyping, particularly in patients followed prospectively over time. Bioassay Core (Core B) is designed to serve the Research Base as a centralized resource for standardized preparation and storage of clinical samples, and for conducting a range of high quality, low-cost assays on clinically derived material. The latter will include both assays performed using commercial kits, as well as custom-designed assays. In the past 5 years, the Bioassay Core has proven its ability to serve the Research base by providing crucial biospecimens and assays for numerous peer reviewed publications, abstracts, and investigator-initiated grant proposals.
The aim of this proposal is to continue growing this critical resource which fuels innovation, collaboration and facilitiates studies focused on a wide range of rheumatic diseases by researchers across the spectrum of investigation. Major services and assays that will be provided by the Bioassay Core include sample preparation (eg, serum, DNA, RNA, PBMCs), storage and retrieval, as well as ELISAs, autoantibody analyses and immunohistochemistry. The Core will also help to connect investigators to other appropriate institutional Cores, and participate in outreach activities. Core B will also provide training, management and quality control to staff in the Clinical Centers to ensure that best practice standards for processing, recordkeeping, and ensuring fidelity of labeling are uniformly applied, and to aid Investigators to take any custom assays established in the Core back to their own labs. The Core will be led by Dr. Livia Casciola-Rosen, who has been Director of this project for the past 3 years, and has many years experience in immunology and assay development. Additional leadership will be provided by Dr. Felipe Andrade and Dr. Laura Gutierrez. The availability of central systems to facilitate sample collection, processing, storage and assays has been critical to enabling scholarship on human rheumatic disease cohorts. The close coordination of this Core with the Administrative, Flow Cytometry and Human Subjects Research and Analytical Cores provides an extremely powerful matrix to maximize synergies in the environment.

Public Health Relevance

This Bioassay Core provides systems and infrastructure to enhance research on humans with autoimmune rheumatic diseases. Collection of samples, and their processing, storage, transport, and assay, in a highly standardized way, provides economy of scale and uniform quality difficult to achieve by individual investigators working alone. It will also facilitate the connection of investigators, collaborators and techniques that they could not easily access alone.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-MLB)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Mecoli, Christopher A; Delev, Nikolay G; Bingham 3rd, Clifton O (2016) Measuring transaminases in patients with rheumatoid arthritis on weekly methotrexate: does timing of blood testing matter? Clin Rheumatol 35:3053-3056
Bouquet, Jerome; Soloski, Mark J; Swei, Andrea et al. (2016) Longitudinal Transcriptome Analysis Reveals a Sustained Differential Gene Expression Signature in Patients Treated for Acute Lyme Disease. MBio 7:e00100-16
Bingham 3rd, Clifton O; Bartlett, Susan J; Merkel, Peter A et al. (2016) Using patient-reported outcomes and PROMIS in research and clinical applications: experiences from the PCORI pilot projects. Qual Life Res 25:2109-16
McMahan, Zsuzsanna H; Cottrell, Tricia R; Wigley, Fredrick M et al. (2016) Enrichment of Scleroderma Vascular Disease-Associated Autoantigens in Endothelial Lineage Cells. Arthritis Rheumatol 68:2540-9
Cappelli, Laura C; Shah, Ami A; Bingham 3rd, Clifton O (2016) Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. RMD Open 2:e000321
Fava, Andrea; Cimbro, Raffaello; Wigley, Fredrick M et al. (2016) Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. Arthritis Res Ther 18:99
McMahan, Zsuzsanna H; Wigley, Fredrick M; Casciola-Rosen, Livia (2016) Increased risk of digital vascular events in scleroderma patients who have both anti-centromere and anti-interferon-inducible protein 16 antibodies. Arthritis Care Res (Hoboken) :
Park, Jin Kyun; Fava, Andrea; Carrino, John et al. (2016) Association of Acroosteolysis With Enhanced Osteoclastogenesis and Higher Blood Levels of Vascular Endothelial Growth Factor in Systemic Sclerosis. Arthritis Rheumatol 68:201-9
Xu, George J; Shah, Ami A; Li, Mamie Z et al. (2016) Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proc Natl Acad Sci U S A 113:E7526-E7534
Birnbaum, Julius; Atri, Nidhi M; Baer, Alan N et al. (2016) The Relationship Between the Neuromyelitis Optica Spectrum Disorder and Sjögren's Syndrome: Central Nervous System Extraglandular Disease or Unrelated, Co-occurring Autoimmunity? Arthritis Care Res (Hoboken) :

Showing the most recent 10 out of 94 publications